• Search History (Register)
  • MeSH Browser
    • Afrikaans
      Albanian
      Arabic
      Armenian
      Basque
      Bengali
      Bulgarian
      Catalan
      Cambodian
      Chinese (Mandarin)
      Chinese (Cantonese)
      Croatian
      Czech
      Danish
      Dutch
      English
      Estonian
      Fiji
      Finnish
      French
      Georgian
      German
      Greek
      Gujarati
      Hebrew
      Hindi
      Hungarian
      Icelandic
      Indonesian
      Irish
      Italian
      Japanese
      Javanese
      Korean
      Latin
      Latvian
      Lithuanian
      Macedonian
      Malay
      Malayalam
      Maltese
      Maori
      Marathi
      Mongolian
      Nepali
      Norwegian
      Persian
      Polish
      Portuguese
      Punjabi
      Quechua
      Romanian
      Russian
      Samoan
      Serbian
      Slovak
      Slovenian
      Spanish
      Swahili
      Swedish
      Tamil
      Tatar
      Telugu
      Thai
      Tibetan
      Tonga
      Turkish
      Ukrainian
      Urdu
      Uzbek
      Vietnamese
      Welsh
      Xhosa
      Apply
    • Adelaide Health Technology Assessment
      Agence d'évaluation des technologies et des modes d'intervention en santé
      Agencia de Evaluacion de Tecnologias Sanitarias
      Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)
      Agencia de Qualitat i Avaluacio Sanitries de Catalunya
      Agency for Care Effectiveness (ACE)
      Agency for Health Technology Assessment and Tariff System
      Agency for Healthcare Research and Quality
      Agenzia Sanitaria e Sociale Regionale (Regional Agency for Health and Social Care)
      All Wales Medicines Strategy Group
      Andalusian Health Technology Assessment Area
      Australian Health Technology Advisory Committee
      Australian Safety and Efficacy Register of New Interventional Procedures-Surgical
      Austrian Institute for Health Technology Assessment
      Basque Office for Health Technology Assessment
      Belgian Health Care Knowledge Centre
      BlueCross BlueShield Association
      British Columbia Office of Health Technology Assessment
      Canadian Agency for Drugs and Technologies in Health
      Canadian Coordinating Office for Health Technology Assessment
      Canadian Task Force on Preventive Health Care
      Canary Health Service
      Cellule Innovation of the AP-HP
      Center for Drug Evaluation
      Center for Medical Technology Assessment
      Center for Outcomes Research and Economic Evaluation for Health
      Centre for Clinical Effectiveness
      Centre for Reviews and Dissemination
      Centre for Technology Assessment at the Swiss Science and Technology Council
      Centre Hospitalier de l'Universite de Montreal
      Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale
      Committee for New Health Technology Assessment
      Conseil d'Evaluation des Technologies de la Santé du Québec
      Coordenação-Geral de Fomento à Pesquisa e Avaliação de Tecnologias em Saúde, Departamento de Ciência e Tecnologia
      Danish Centre for Evaluation and Health Technology Assessment
      Danish Institute for Health Services Research
      ECRI Institute
      European Network for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore
      German Agency for HTA at the German Institute for Medical Documentation and Information
      Gesundheit Osterreich GmbH
      Hannover Medical School, Medizinische Hochschule Hannover
      Haute Autorité de Santé
      HAYES, Inc.
      Health Council of the Netherlands Gezondheidsraad
      Health Information and Quality Authority (HIQA)
      Health Intervention and Technology Assessment Program
      Health Quality Ontario
      Health Sciences Institute in Aragon (IACS)
      Health Services Assessment Collaboration
      Health Services Utilization and Research Commission
      Health Technology Advisory Committee
      Health Technology and Policy Unit
      Health Technology Assessment Section, Ministry of Health Malaysia
      Health Technology Board for Scotland
      Health Technology Reference Group
      Health Technology Wales
      HTA Region Stockholm
      HTA South
      HTA Unit, University of Calgary
      Institut national d'excellence en sante et en services sociaux
      Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval)
      Institute for Clinical and Economic Review
      Institute for Clinical Effectiveness and Health Policy
      Institute for Clinical Evaluative Sciences
      Institute for Clinical Systems Improvement
      Institute for Quality and Efficiency in Health Care (IQWiG)
      Institute of Applied Health Sciences
      Institute of Health Economics
      Institute of Health Economics
      Institute of Health Technology Assessment and Research (IETSI)
      Institute of Technology Assessment
      Israel Center for Technology Assessment in Health Care
      L'Agence Nationale d'Accreditation d'Evaluation en Santé
      Ludwig Boltzmann Institute for Health Technology Assessment
      Malaysian Health Technology Assessment
      Malaysian Health Technology Assessment Unit
      Medical Advisory Secretariat
      Medical Services Advisory Committee
      Monash Business School, Monash University (MBS)
      National Authority for Assessment and Accreditation in Healthcare (INEAS)
      National Committee for Technology Incorporation (CONITEC)
      National Evidence-based healthcare Collaborating Agency
      National Institute for Clinical Excellence
      National Institute for Health and Care Excellence
      New Zealand Health Technology Assessment
      New Zealand National Health Committee
      NIHR Health and Social Care Delivery Program
      NIHR Health Services and Delivery Research programme
      NIHR Health Technology Assessment programme
      NIHR Horizon Scanning Centre
      NIHR Public Health Research programme
      Norwegian Institute of Public Health
      Norwegian Institute of Public Health
      Norwegian Medical Products Agency
      Ontario Health
      Penn Medicine Center for Evidence-based Practice
      Quality Improvement Scotland
      Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)
      Scottish Health Purchasing Information Centre
      Scottish Health Technologies Group
      Scottish Medicines Consortium (SMC)
      State Health Care Accreditation Agency under the Ministry of Health of the Republic of Lithuania
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swiss Federal Office of Public Health (FOPH)
      Technology Assessment at SickKids
      Technology Assessment Unit of the McGill University Health Centre (MUHC)
      The Danish Health Technology Council
      The Federal Joint Committee
      The HTA Center of the Stockholm County Council/Gotland
      The Italian National Agency for Regional Health Services (Agenas)
      The National Health Care Institute (ZIN, Zorginstituut Nederland)
      The National Health Care Institute (Zorginstituut Nederland)
      The Netherlands Organisation for Health Research and Development
      The Regional Health Technology Assessment Centre
      TNO
      U. S. Congress. Office of Technology Assessment
      Unidad de Evaluacion de Tecnologias Sanitarias
      Unidad de Tecnologias de Salud
      Unit of Health Economics and Technology Assessment in Health Care
      University HealthSystem Consortium
      University of York
      VA Technology Assessment Program
      Washington Singer Press
      Washington State Department of Labor and Industries (WSDLI)
      Wessex Institute for Health Research and Development
      West Midlands Health Technology Assessment Collaboration
      WorkSafeBC
      Apply
    • Afghanistan
      Albania
      Algeria
      Andorra
      Antigua and Barbuda
      Argentina
      Armenia
      Australia
      Austria
      Azerbaijan
      Bahamas
      Bahrain
      Bangladesh
      Barbados
      Belarus
      Belgium
      Belize
      Benin
      Bhutan
      Bolivia
      Bosnia and Herzegovina
      Botswana
      Brazil
      Brunei
      Bulgaria
      Burkina Faso
      Burundi
      Cambodia
      Cameroon
      Canada
      Cape Verde
      Central African Republic
      Chad
      Chile
      China
      Colombia
      Comoros
      Congo
      Costa Rica
      Cote dIvoire
      Croatia
      Cuba
      Cyprus
      Czech Republic
      Denmark
      Djibouti
      Dominica
      Dominican Republic
      East Timor
      Ecuador
      Egypt
      El Salvador
      Equatorial Guinea
      Eritrea
      Estonia
      Ethiopia
      Fiji
      Finland
      France
      Gabon
      Gambia
      Georgia
      Germany
      Ghana
      Greece
      Grenada
      Guatemala
      Guinea
      Guinea-Bissau
      Guyana
      Haiti
      Honduras
      Hong Kong
      Hungary
      Iceland
      India
      Indonesia
      Iran
      Iraq
      Ireland
      Israel
      Italy
      Jamaica
      Japan
      Jordan
      Kazakhstan
      Kenya
      Kiribati
      North Korea
      South Korea
      Kuwait
      Kyrgyzstan
      Laos
      Latvia
      Lebanon
      Lesotho
      Liberia
      Libya
      Liechtenstein
      Lithuania
      Luxembourg
      Macedonia
      Madagascar
      Malawi
      Malaysia
      Maldives
      Mali
      Malta
      Marshall Islands
      Mauritania
      Mauritius
      Mexico
      Micronesia
      Moldova
      Monaco
      Mongolia
      Montenegro
      Morocco
      Mozambique
      Myanmar
      Namibia
      Nauru
      Nepal
      Netherlands
      New Zealand
      Nicaragua
      Niger
      Nigeria
      Norway
      Oman
      Pakistan
      Palau
      Panama
      Papua New Guinea
      Paraguay
      Peru
      Philippines
      Poland
      Portugal
      Puerto Rico
      Qatar
      Romania
      Russia
      Rwanda
      Saint Kitts and Nevis
      Saint Lucia
      Saint Vincent and the Grenadines
      Samoa
      San Marino
      Sao Tome and Principe
      Saudi Arabia
      Senegal
      Serbia and Montenegro
      Seychelles
      Sierra Leone
      Singapore
      Slovakia
      Slovenia
      Solomon Islands
      Somalia
      South Africa
      Spain
      Sri Lanka
      Sudan
      Suriname
      Swaziland
      Sweden
      Switzerland
      Syria
      Taiwan
      Tajikistan
      Tanzania
      Thailand
      Togo
      Tonga
      Trinidad and Tobago
      Tunisia
      Turkey
      Turkmenistan
      Tuvalu
      Uganda
      Ukraine
      United Arab Emirates
      United Kingdom
      United States
      Uruguay
      Uzbekistan
      Vanuatu
      Vatican City
      Venezuela
      Vietnam
      Yemen
      Zambia
      Zimbabwe
      Apply

Welcome to the international HTA database

CSV RIS
Showing [23378 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2022     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Evaluation of the safety, efficacy/effectiveness, and efficiency of teleconsultation in primary care, and the organizational, ethical, social, and legal aspects linked to its use]
2022     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Evaluation of the safety, efficacy/effectiveness, and efficiency of stereotactic body radiation therapy (SBRT) in lung, prostate, and liver cancer]
2023     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Evaluation of the safety, diagnostic validity, and clinical effectiveness of transcutaneous measurement of partial pressure of oxygen in the management of diabetic foot]
2010     The Netherlands Organisation for Health Research and Development (ZonMw) [Evaluation of the potential of real-time 3-dimensional echocardiography in the assessment of right ventricular function in adult congenital heart disease: comparison of RT-3D echo with MRI]
2023     Center for Drug Evaluation (CDE) [Evaluation of the optimal fixed subsidies strategy for pneumococcal vaccination in the elderly]
2023     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Evaluation of the lung cancer screening program]
2023     Canary Health Service [Evaluation of the lung cancer screening program]
2012     Basque Office for Health Technology Assessment (OSTEBA) [Evaluation of the implementation of clinical guidelines in the Basque Country. Cluster randomized trial]
2012     Institut national d'excellence en sante et en services sociaux (INESSS) [Evaluation of the evidence on the HeartMate II and HeartWare ventricular assist devices for the treatment of chronic end-stage heart failure]
2005     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Evaluation of the efficacy and safety of negative pressure in the treatment of chronic wounds]
2014     Basque Office for Health Technology Assessment (OSTEBA) [Evaluation of the effectiveness of psychological intervention in the first psychotic episode by multidisciplinary treatment]
2023     Center for Drug Evaluation (CDE) [Evaluation of the effectiveness of long-acting antipsychotic injections and future recommendations for mental health care in Taiwan's National Health Insurance System]
2021     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Evaluation of the effectiveness of hip and knee implant models used by the Spanish National Health System]
2009     Canary Health Service [Evaluation of the effectiveness and costs of Quantiferon-TB Gold for the diagnosis of latent tuberculosis infection in healthcare personnel]
2019     Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval) [Evaluation of the effectiveness and cost effectiveness of cardiac rehabilitation programs]
2004     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Evaluation of the Danish National Cancer Action Plan - status and future monitoring - summary and proposals for focus areas]
2020     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Evaluation of the clinical effectiveness and safety of primary shoulder arthroplasty]
2005     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evaluation of the benefits and harms of statins (with particular consideration of atorvastatin)]
2016     Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval) [Evaluation of technologies allowing the induction of therapeutic hypothermia in patients who have suffered a cardiac arrest]
2003     Agence d'évaluation des technologies et des modes d'intervention en santé (AETMIS) [Evaluation of techniques for detecting breast implant rupture]
2023     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Evaluation of taking mifepristone at home during a medical abortion]
2011     Andalusian Health Technology Assessment Area (AETSA) [Evaluation of surrogate variables in oncology. Advanced and metastatic breast cancer]
2016     Institut national d'excellence en sante et en services sociaux (INESSS) [Evaluation of subcutaneous-lead implantable cardioverter-defibrillators]
2019     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Evaluation of strategies to prevent urinary tract infections related to urethral catheters in critically ill patients in intensive care units]
2022     Agencia de Evaluacion de Tecnologias Sanitarias (AETS) [Evaluation of several vaccination strategies against rotavirus in Spain. Safety, efficacy, effectiveness and efficiency]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evaluation of regular searches in the ICTRP Search Portal]
2021     Norwegian Institute of Public Health (NIPH) [Evaluation of PD-L1 assays in urothelial carcinoma: a rapid HTA]
2023     Canary Health Service [Evaluation of patient involvement in health technology assessment]
2007     German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) [Evaluation of optical coherence tomography in the diagnosis of age related macular degeneration compared with fluorescence angiography]
2010     Haute Autorite de sante (HAS) [Evaluation of negative-pressure wound therapy]
2011     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [Evaluation of multiple technologies for chronic wounds and burns]
2021     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Evaluation of mHealth-based technology for mobile applications]
2009     German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) [Evaluation of medical and health economic effectiveness of non-pharmacological secondary prevention of coronary heart disease]
2008     German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) [Evaluation of medical and health economic effectiveness of bariatric surgery (obesity surgery) versus conservative strategies in adult patients with morbid obesity]
2014     Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval) [Evaluation of measures related to the prevention of multiple falls in hospitalized elderly people]
2009     The Netherlands Organisation for Health Research and Development (ZonMw) [Evaluation of l-caldesmon as biomarker for brain tumor monitoring]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evaluation of invitation letters and information for insured persons on colorectal cancer screening]
2009     Finnish Office for Health Care Technology Assessment (Finohta) [Evaluation of implementation of foetal screening]
2016     Haute Autorite de sante (HAS) [Evaluation of gene amplification for diagnosis Herpesviridae infections (cytomegalovirus, herpes simplex virus and varicella-zoster) in people living with HIV]
2009     Agence d'évaluation des technologies et des modes d'intervention en santé (AETMIS) [Evaluation of ethylene oxide sterilant alternatives: plasma and ozone]
2014     Unidad de Evaluacion de Tecnologias Sanitarias (UETS) [Evaluation of efficiency of organizational models for stroke management (stroke units)]
2013     Unidad de Evaluacion de Tecnologias Sanitarias (UETS) [Evaluation of efficacy and safety of PET-CT (update)]
2023     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Evaluation of early intervention programs in psychosis for adolescents and young adults]
2010     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Evaluation of diagnostic technologies - background, challenges, methods]
2016     Basque Office for Health Technology Assessment (OSTEBA) [Evaluation of care times for the main cancer sites: colon/rectum, lung, breast and prostate]
2014     Basque Office for Health Technology Assessment (OSTEBA) [Evaluation of care quality in the national health service towards severe childhood mental disorders. A study in infant/juvenile mental health services]
2013     Basque Office for Health Technology Assessment (OSTEBA) [Evaluation of bubble humidification systems in low-flow oxygen therapy. Systematic review and cost analysis]
2010     Canary Health Service [Evaluation of an intervention on smoking in secondary education. ITES Program]
2018     Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval) [Evaluation of ambulatory electrocardiography technologies for the diagnosis of cardiac arrhythmia]
2013     Basque Office for Health Technology Assessment (OSTEBA) [Evaluation and impact of a primary care-based telemonitoring intervention in home care patients with heart failure or chronic lung disease. Randomised controlled trial. The TELBIL study]
2013     Basque Office for Health Technology Assessment (OSTEBA) [Evaluating the implementation of diagnostic telemedicine in the field of dermatology]
2012     National Evidence-based Healthcare Collaborating Agency (NECA) [Evaluating the health service and inequality in the health insurance coverage expansion for cancer; Before and after study: Part 2: Evaluation of the impact in inequality before and after the enhancement of health insurance coverage of cancer]
2012     National Evidence-based Healthcare Collaborating Agency (NECA) [Evaluating the health service and inequality in the health insurance coverage expansion for cancer; Before and after study: Part 1: Evaluation of the change in medical services before and after the enhancement of health insurance coverage of cancer]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Etranacogene dezaparvovec (haemophilia B) - Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2014     Institut national d'excellence en sante et en services sociaux (INESSS) [ETIAMEST I & II: Highlights]
2017     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Etelcalcetide (secondary hyperparathyroidism) - Benefit assessment according to §35a Social Code Book V]
2017     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Etelcalcetide (secondary hyperparathyroidism) - Addendum]
2013     Institute for Clinical Effectiveness and Health Policy (IECS) [Etanercept, adalimumab, infliximab and golimumab for the treatment of juvenile idiopathic arthritis]
2006     Unit of Health Economics and Technology Assessment in Health Care (HunHTA) [Etanercept in patients with juvenile idiopathic arthritis: systematic review and economic evaluation]
2014     Canary Health Service [Estimation of the set of values for the health states of the EQ-5D-5L based on the preferences of the Spanish population]
2010     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) [Estimation of incidence of urinary incontinence associated with pregnancy and childbirth]
2003     Center for Medical Technology Assessment (CMT) [Estimating health care need]
2013     Andalusian Health Technology Assessment Area (AETSA) [Esteem® totally implantable hearing device for treatment of sensorineural hearing loss. Systematic review]
2008     Basque Office for Health Technology Assessment (OSTEBA) [Establishing standards, records and analytical procedures for the treatment of ulcerative colitis]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Esketamine (treatment-resistant major depressive disorder) – Benefit assessment according to §35a Social Code Book V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Esketamine (treatment-resistant major depressive disorder) – Addendum to Commission A23-18]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Esketamine (depression) - Benefit assessment according to §35a Social Code Book V]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Esketamine (depression, acute treatment) - Benefit assessment according to §35a Social Code Book V]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Esketamine (depression, acute treatment) - Addendum to Commission A21-25]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ertugliflozin/sitagliptin (type 2 diabetes mellitus) - Benefit assessment according to §35a Social Code Book V]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ertugliflozin (type 2 diabetes mellitus) - Benefit assessment according to §35a Social Code Book V]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ertugliflozin (type 2 diabetes mellitus) - Addendum to Commission A21-158]
2016     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Eribulin (new therapeutic indication) - Benefit assessment according to §35a Social Code Book V]
2014     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Eribulin (new therapeutic indication) - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2016     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Eribulin (liposarcoma) - Addendum A16-31
2015     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Eribulin (Addendum to Commission A14-25)]
2012     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Eribulin - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2019     Institute for Clinical Effectiveness and Health Policy (IECS) [Erenumab in migraine prevention]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Erenumab (prophylaxis of migraine) - Benefit assessment according to §35a Social Code Book V]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Erenumab (migraine) - Benefit assessment according to §35a Social Code Book V (new scientific findings)]
2009     Committee for New Health Technology Assessment (CNHTA) [ERCC1 RNA RT-PCR quantification]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Eravacycline (complicated intra-abdominal infections) - Assessment according to §35a (para. 1c) Social Code Book V]
2021     Institute for Clinical Effectiveness and Health Policy (IECS) [Equine immunoglobulin F(ab’)2 fragments (hyperimmune equine serum) for COVID-19]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Eptinezumab (migraine) - Benefit assessment according to §35a Social Code Book V]
2009     Committee for New Health Technology Assessment (CNHTA) [Epstein-Barr virus VCA IgA]
2009     Committee for New Health Technology Assessment (CNHTA) [Epstein-Barr virus EA IgA]
2019     Institute for Clinical Effectiveness and Health Policy (IECS) [Eposterior tibial nerve stimulation in overactive bladder and bowel incontinence]
2004     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Epoetin (EPO) for anaemic cancer patients]
2007     The Netherlands Organisation for Health Research and Development (ZonMw) [Epileptic source localization with EEG-correlated functional MRI]
2018     Andalusian Health Technology Assessment Area (AETSA) [Epigenetic profile for the identification of primary cancer of unknown origin]
2018     Canary Health Service [Epidermal growth factor for the treatment of diabetic foot ulcers]
2017     Institute for Clinical Effectiveness and Health Policy (IECS) [Epidermal growth factor (Heberprot-P®) in chronic ulcers]
2021     Austrian Institute for Health Technology Assessment (AIHTA) [Epidemiology of long COVID: a preliminary report. German short version of the original KCE report]
2003     Unit of Health Economics and Technology Assessment in Health Care (HunHTA) [Epidemiology and costs of osteoarthritis and rheumatoid arthritis in Hungary]
2008     Basque Office for Health Technology Assessment (OSTEBA) [Epidemiological analysis of information collected by hospital cancer registries in the Basque Autonomous Community. Identification of possible improvements with regard to the feedback and dissemination of results]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Epcoritamab (relapsed or refractory diffuse large B-cell lymphoma) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2011     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) [Enzyme replacement therapy in mucopolysaccharidoses I, II and VI; 2011]
2018     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Enzyme replacement therapy in lysosomal storage diseases: systematic review and budgetary impact. Update]
2011     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) [Enzymatic replacement treatment for type I gaucher's disease patients]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Enzalutamide (prostate cancer) - Benefit assessment according to §35a Social Code Book V]